ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Liver Enzyme Elevations Fly In Ointment?

Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.    

Servier At ASCO • Source: Alaric DeArment

Servier’s late 2020 decision to pay $1.8bn for Agios Pharmaceuticals, Inc.’ cancer portfolio appears to be paying off handsomely with the lead investigational product from that transaction, vorasidenib, looking set to provide the first targeted treatment for low-grade glioma.

Full data from the Phase III INDIGO presented at the American Society of Clinical Oncology meeting in Chicago on 4...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from ASCO

More from Conferences